These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18708615)

  • 1. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Sahu AK; Majji AB
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    ; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ; Aiello LP; Davis MD; Danis R; Bek T; Cunha-Vaz J; Shahri N; Berg PH;
    Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1750-7. PubMed ID: 23404115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
    PKC-DMES Study Group
    Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
    Gardner TW; Larsen M; Girach A; Zhi X;
    Acta Ophthalmol; 2009 Nov; 87(7):709-13. PubMed ID: 19817721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
    Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
    Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
    Strøm C; Sander B; Klemp K; Aiello LP; Lund-Andersen H; Larsen M
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3855-8. PubMed ID: 16186374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group
    Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
    Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
    Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medications for diabetic macular edema].
    Kitano S
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():275-9. PubMed ID: 15999719
    [No Abstract]   [Full Text] [Related]  

  • 14. Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.
    Gálvez MI
    Curr Diabetes Rev; 2009 Feb; 5(1):14-7. PubMed ID: 19199893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.
    Girach A; Aiello LP; Milton RC; Davis MD; Danis RP; Zhi X; Sheetz MJ; Vignati L;
    Eye (Lond); 2009 Jan; 23(1):209-14. PubMed ID: 18989348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruboxistaurin for diabetic retinopathy.
    Gardner TW; Antonetti DA
    Ophthalmology; 2006 Dec; 113(12):2135-6. PubMed ID: 17157131
    [No Abstract]   [Full Text] [Related]  

  • 18. [New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].
    Lagrèze WA
    MMW Fortschr Med; 2003 Apr; 145(14):37-8. PubMed ID: 15072277
    [No Abstract]   [Full Text] [Related]  

  • 19. [Results of the treatment of diffuse diabetic macular edema by laser coagulation of the scatter grid type. Preliminary report].
    Nawrocka Z; Nawrocki J; Swietliczko I
    Klin Oczna; 1991 Sep; 93(9):259-61. PubMed ID: 1816460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.